Search
Photo: Attila Csaszar

Pfleger taking medical research out of the lab

40under40: Kevin Pfleger is on a mission to turn WA medical research into solutions for chronic disease.

Resilience, a dedicated team and a supportive family have been the key drivers of Kevin Pfleger's research and clinical success, which have sparked international interest from the likes of Takeda, Japan’s largest pharmaceutical company.

Dr Pfleger studies how hormones, neurotransmitters and pharmaceuticals work on cells in the body at the molecular level, and his findings so far have led to the co-invention of two medical approaches to tackling chronic disease.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Register for free

Sign up here for free access to 7 articles per month + twice daily business email alerts.

CAPTCHA
Thanks! This question prevents spammers...
Image CAPTCHA
Enter the characters shown in the image.

Add your comment

Dimerix (DXB)

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 30/06/17

1 year TSR5 year TSR
25thFastbrick Robotics320%62%
191stDimerix43%58%
198thSportsHero41%-57%
742ndWeebit-Nano-63%-41%
750thShark Mitigation Systems-67%0%
711 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

30/06/17
$0 Other
30/06/17
$0 Other
30/06/17
$0 Other
Total value as at the date of the transaction
Source: Morningstar

Revenue

140th-Dimerix$565k
143rd-Shark Mitigation Systems$380k
144th-SportsHero$294k
146th↑Fastbrick Robotics$253k
147th-Weebit-Nano$237k
230 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer